Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
- PMID: 34509185
- PMCID: PMC8428469
- DOI: 10.1016/S1473-3099(21)00479-5
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study
Abstract
Background: By July 14, 2021, 81·3 % of adults (aged ≥18 years) in Chile had received a first SARS-CoV-2 vaccine and 72·3% had received a second SARS-CoV-2 vaccine, with the majority of people given Sinovac's inactivated CoronaVac vaccine (75·3% of vaccines dispensed) or Pfizer-BioNTech's mRNA BNT162b2 vaccine (20·9% of vaccines dispensed). Due to the absence of simultaneous real-world data for these vaccines, we aimed to compare SARS-CoV-2 IgG positivity between vaccines using a dynamic national monitoring strategy.
Methods: From March 12, 2021, 28 testing stations for SARS-CoV-2 IgG detection were installed in hotspots based on cellular-phone mobility tracking within the most populated cities in Chile. Individuals voluntarily approaching the testing stations were invited to do a lateral flow test by finger prick and respond to a questionnaire on sociodemographic characteristics, vaccination status (including type of vaccine if one was received), variables associated with SARS-CoV-2 exposure, and comorbidities. We compared the proportion of individuals testing positive for anti-SARS-CoV-2 IgG across sites by week since vaccination between recipients of CoronaVac and BNT162b2. Unvaccinated participants served as a control population and were matched to vaccinated individuals on the basis of date of presentation to the testing station, gender, and age group. Individuals were excluded from the analysis if they were younger than 18 years, had no declared gender, had an invalid IgG test result, had previously tested positive for SARS-CoV-2 infection on PCR, could not recall their vaccination status, or had been immunised against COVID-19 with vaccines other than CoronaVac or BNT162b2. Here, we report data collected up to July 2, 2021.
Findings: Of 64 813 individuals enrolled, 56 261 were included in the final analysis, of whom 33 533 (59·6%) had received at least one dose of the CoronaVac vaccine, 8947 (15·9%) had received at least one dose of the BNT162b2 vaccine, and 13 781 (24·5%) had not received a vaccine. SARS-CoV-2 IgG positivity during week 4 after the first dose of CoronaVac was 28·1% (95% CI 25·0-31·2; 220 of 783 individuals), reaching a peak of 77·4% (75·5-79·3; 1473 of 1902 individuals) during week 3 after the second dose. SARS-CoV-2 IgG positivity during week 4 after the first dose of the BNT162b2 vaccine was 79·4% (75·7-83·1; 367 of 462 individuals), increasing to 96·5% (94·9-98·1; 497 of 515 individuals) during week 3 after the second dose and remaining above 92% until the end of the study. For unvaccinated individuals, IgG seropositivity ranged from 6·0% (4·4-7·6; 49 of 810 individuals) to 18·7% (12·5-24·9; 28 of 150 individuals) during the 5 month period. Regression analyses showed that IgG seropositivity was significantly lower in men than women and in people with diabetes or chronic diseases for CoronaVac vaccine recipients (p<0·0001), and for individuals aged 60 years and older compared with people aged 18-39 years for both vaccines (p<0·0001), 3-16 weeks after the second dose.
Interpretation: IgG seropositivity was lower after CoronaVac than after BNT162b2 and declined over time since vaccination for CoronaVac recipients but not BNT162b2 recipients. Prolonged IgG monitoring will allow further evaluation of seropositivity overtime, providing data, in conjunction with effectiveness studies, for possible future re-assessment of vaccination strategies.
Funding: Instituto Sistemas Complejos de Ingeniería and Ministerio de Salud Chile.
Translation: For the Spanish translation of the abstract see Supplementary Materials section.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Figures
Comment in
-
Protection against COVID-19: beyond antibodies.Lancet Infect Dis. 2022 Jan;22(1):4-5. doi: 10.1016/S1473-3099(21)00561-2. Epub 2021 Sep 9. Lancet Infect Dis. 2022. PMID: 34509186 Free PMC article. No abstract available.
Similar articles
-
COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.Lancet Microbe. 2023 Mar;4(3):e149-e158. doi: 10.1016/S2666-5247(22)00290-7. Epub 2023 Jan 27. Lancet Microbe. 2023. PMID: 36716754 Free PMC article.
-
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.Lancet Microbe. 2022 Apr;3(4):e274-e283. doi: 10.1016/S2666-5247(21)00305-0. Epub 2022 Feb 9. Lancet Microbe. 2022. PMID: 35165669 Free PMC article.
-
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12. Lancet Infect Dis. 2023. PMID: 36521506 Free PMC article.
-
Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD015021. doi: 10.1002/14651858.CD015021. Cochrane Database Syst Rev. 2022. PMID: 35943061 Free PMC article. Review.
-
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.Eur J Cancer. 2021 Dec;159:259-274. doi: 10.1016/j.ejca.2021.10.013. Epub 2021 Oct 25. Eur J Cancer. 2021. PMID: 34798454 Free PMC article. Review.
Cited by
-
Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.BMC Infect Dis. 2024 May 3;24(1):467. doi: 10.1186/s12879-024-09304-1. BMC Infect Dis. 2024. PMID: 38698324 Free PMC article.
-
Transdisciplinary research before, during and after COVID-19 vaccination in Chile: a virtuoso collaboration with future perspectives.Front Public Health. 2024 Apr 3;12:1354645. doi: 10.3389/fpubh.2024.1354645. eCollection 2024. Front Public Health. 2024. PMID: 38633235 Free PMC article. Review.
-
Pathophysiological, immunological, and inflammatory features of long COVID.Front Immunol. 2024 Feb 28;15:1341600. doi: 10.3389/fimmu.2024.1341600. eCollection 2024. Front Immunol. 2024. PMID: 38482000 Free PMC article. Review.
-
The dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol.F1000Res. 2024 Feb 23;11:1392. doi: 10.12688/f1000research.126577.2. eCollection 2022. F1000Res. 2024. PMID: 38434000 Free PMC article.
-
Comparative analysis of antibody responses to BNT162b2, ChAdOx1, and CoronaVac vaccines in the Albanian population over the pandemic years 2021 to 2022.Clin Exp Vaccine Res. 2024 Jan;13(1):63-67. doi: 10.7774/cevr.2024.13.1.63. Epub 2024 Jan 31. Clin Exp Vaccine Res. 2024. PMID: 38362369 Free PMC article.
References
-
- Department of Statistics and Information. Ministry of Health Chile Official figures COVID-19 Chile. 2021. https://deis.minsal.cl/ (in Spanish).
-
- Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. 2021 doi: 10.2139/ssrn.3822780. published online April 14. (preprint). - DOI
-
- Instituto Sistemas Complejos de Ingeniería Seroprevalence. 2021. https://covidanalytics.isci.cl/seroprevalencia/
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous